Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cue Biopharma (CUE) Revenue (2018 - 2025)

Cue Biopharma's Revenue history spans 8 years, with the latest figure at $2.1 million for Q3 2025.

  • For Q3 2025, Revenue fell 35.58% year-over-year to $2.1 million; the TTM value through Sep 2025 reached $7.1 million, down 25.52%, while the annual FY2024 figure was $9.3 million, 69.16% up from the prior year.
  • Revenue for Q3 2025 was $2.1 million at Cue Biopharma, down from $3.0 million in the prior quarter.
  • Across five years, Revenue topped out at $8.3 million in Q4 2021 and bottomed at $26000.0 in Q2 2022.
  • The 5-year median for Revenue is $1.7 million (2024), against an average of $1.9 million.
  • The largest annual shift saw Revenue plummeted 99.05% in 2022 before it skyrocketed 5219.23% in 2023.
  • A 5-year view of Revenue shows it stood at $8.3 million in 2021, then plummeted by 98.17% to $151000.0 in 2022, then skyrocketed by 1105.3% to $1.8 million in 2023, then dropped by 13.41% to $1.6 million in 2024, then soared by 36.36% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for CUE's Revenue are $2.1 million (Q3 2025), $3.0 million (Q2 2025), and $421000.0 (Q1 2025).